InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by Saik Andrew, Chief Financial Officer. Officer active across 2 companies, notably VYNE Therapeutics Inc.. Aggregated, 7 reports have been published. The latest transaction was filed on 21 June 2022 — Retenue fiscale. Regulator: SEC (Form 4). The full history is openly available.
Declarations7 total
€43,0353,632 shares@ €11.8489100.0% of flow
Common Stock
SEC:0001104659-22-073886:0·
010,300 shares0
Common Stock
SEC:0001104659-22-009563·
010,300 shares0
Common Stock
SEC:0001104659-22-009563:0·
052,156 shares0
Common Stock
SEC:0001104659-21-084279·
052,156 shares0
Common Stock
SEC:0001104659-21-084279:0·
€8,3083,017 shares@ €2.75360.043% mcap100.0% of flow
Common Stock
SEC:0001209191-21-037193·
€8,3083,017 shares@ €2.75360.043% mcap50.0% of flow
Common Stock
SEC:0001209191-21-037193:0·
7 of 7 declarations
About Saik Andrew
Andrew Saik is the Chief Financial Officer and EVP at Vyne Therapeutics Inc. and Intercept Pharmaceuticals, Inc. He is responsible for financial management and strategy for the companies. His expertise in finance enables him to oversee financial operations and ensure transparency in financial reporting. He plays a key role in supporting the financial strategy of these firms.
